Screening characteristics
| n | 17 |
| Sex (M/F) | 14/3 |
| Ethnicity (Caucasian/African-American) | 9/8 |
| Age (years) | 56 ± 3 (37–70) |
| Duration of type 2 diabetes (years) | 7 ± (1–16) |
| Weight (kg) | 102.3 ± 5.2 (69.5–151.5) |
| Height (cm) | 175 ± 2 (157–196) |
| BMI (kg/m2) | 33.1 ± 1.4 (25.1–44.9) |
| HbA1c (%) | 8.8 ± 0.4 (6.1–11.8) |
| Microalbumin (μg/ml) | 83 ± 17 (22–311)* |
| Oral antidiabetic agent/diet (yes/no) | 16/1 |
| Sulfonylureas | 9 |
| Biguanides | 3 |
| Biguanides + sulfonylureas | 4 |
| ACE inhibitor (yes/no) | 8/9 |
| ACE-1 | 6 |
| ARB | 1 |
| ARB or ACE-1 + β-blocker | 1 |
| Systolic blood pressure (mmHg) | 151 ± 4 (111–177)* |
| Diastolic blood pressure (mmHg) | 85 ± 2 (73–94)* |
| Smoke (yes/no) | 3/14 |
| Lipid medications (yes/no) | 4/13 |
| Gemfibrazole | 1 |
| Gemfibrazole + niacin | 1 |
| HMG-CoA reductase inhibitors | 2 |
| n | 17 |
| Sex (M/F) | 14/3 |
| Ethnicity (Caucasian/African-American) | 9/8 |
| Age (years) | 56 ± 3 (37–70) |
| Duration of type 2 diabetes (years) | 7 ± (1–16) |
| Weight (kg) | 102.3 ± 5.2 (69.5–151.5) |
| Height (cm) | 175 ± 2 (157–196) |
| BMI (kg/m2) | 33.1 ± 1.4 (25.1–44.9) |
| HbA1c (%) | 8.8 ± 0.4 (6.1–11.8) |
| Microalbumin (μg/ml) | 83 ± 17 (22–311)* |
| Oral antidiabetic agent/diet (yes/no) | 16/1 |
| Sulfonylureas | 9 |
| Biguanides | 3 |
| Biguanides + sulfonylureas | 4 |
| ACE inhibitor (yes/no) | 8/9 |
| ACE-1 | 6 |
| ARB | 1 |
| ARB or ACE-1 + β-blocker | 1 |
| Systolic blood pressure (mmHg) | 151 ± 4 (111–177)* |
| Diastolic blood pressure (mmHg) | 85 ± 2 (73–94)* |
| Smoke (yes/no) | 3/14 |
| Lipid medications (yes/no) | 4/13 |
| Gemfibrazole | 1 |
| Gemfibrazole + niacin | 1 |
| HMG-CoA reductase inhibitors | 2 |
Data are means ± SE (range) or n.
To meet recruitment goals, microalbumin and blood pressure exclusion criteria were broadened slightly. HMG, hydroxymethylglutaryl.